Tvardi Therapeutics shares are trading lower. The company announced the publication of preclinical ulcerative colitis data supporting its STAT3 inhibitor program.

Tvardi Therapeutics Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In International Journal Of Molecular Sciences

In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. The company's, Q2 earnings came

Tvardi Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.